StockNews.AI

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025

StockNews.AI • 3 hours

JNJAMGNREGN
High Materiality8/10

Information

Company Announcement Net sales of DARZALEX ® in 2025 totaled USD 14,351 million Genmab receives roya...

Original source

AI Summary

Genmab announced worldwide net sales of DARZALEX® reached USD 14.35 billion in 2025, from which they earn royalties under an exclusive license with Johnson & Johnson. This substantial revenue contributes significantly to Genmab's overall financial performance and underlines the product's ongoing success in the market.

Sentiment Rationale

Strong sales figures may enhance investor sentiment and stock price; historical performance indicates high correlation between product sales and stock performance.

Trading Thesis

Buy GMAB; strong DARZALEX revenue signals solid growth potential over the next 12 months.

Market-Moving

  • Strong DARZALEX sales highlight increasing market acceptance and revenue stability.
  • Positive growth trend in sales could enhance Genmab's stock valuation.
  • Significant royalties from J&J bolster Genmab's financial position and future investments.
  • Expansion of DARZALEX product variants may open new revenue streams.

Key Facts

  • Genmab reports DARZALEX® sales of USD 14.35 billion for 2025.
  • U.S. sales reached USD 8.27 billion; international sales totaled USD 6.09 billion.
  • Genmab receives royalties from J&J under an exclusive global license.
  • Company aims to advance antibody-based therapies for serious diseases.
  • DARZALEX continues to be a significant revenue driver for Genmab.

Companies Mentioned

  • Johnson & Johnson (JNJ): J&J's sales of DARZALEX drive significant royalties to Genmab.

Corporate Developments

This falls under 'Corporate Developments' as it showcases significant sales figures affecting Genmab's financial health, driven largely by attributes tied to their partnerships and product success. Such strong sales can influence investor confidence and market positioning.

Genmab Reports 2025 Net Sales of DARZALEX® Totaling USD 14,351 Million

Copenhagen, Denmark; January 21, 2026 – Genmab A/S (Nasdaq: GMAB) today announced its worldwide net trade sales for DARZALEX® (daratumumab) reached an impressive USD 14,351 million in 2025. This figure includes net sales from the subcutaneous (SC) formulation, marketed as DARZALEX FASPRO® in the U.S., as reported by Johnson & Johnson (J&J) subsidiary Janssen Biotech, Inc.

Sales Breakdown and Genmab's Royalties

The net sales of DARZALEX were broken down into:

  • USD 8,266 million in the United States
  • USD 6,085 million from the rest of the world

Genmab benefits from these sales through royalties under its exclusive worldwide license with J&J, which encompasses both the intravenous and SC forms of daratumumab.

About Genmab: A Leader in Antibody Therapies

Established in 1999, Genmab is a global biotechnology company focused on developing innovative antibody medicines aimed at improving the lives of patients with cancer and other serious diseases. With over 25 years of expertise, Genmab has advanced various antibody-based therapeutic formats, including:

  • Bispecific antibodies
  • Antibody-drug conjugates (ADCs)
  • Immune-modulating antibodies
  • Next-generation modalities

Currently, Genmab's science underpins eight approved antibody therapies, and the company boasts a robust late-stage clinical pipeline with several wholly owned programs focused on delivering transformative medicines to patients.

Global Presence and Investor Relations

Headquartered in Copenhagen, Denmark, Genmab maintains a strong international presence, including operations in North America, Europe, and the Asia Pacific region. For inquiries and further information, interested parties can reach out to:

  • Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
  • Phone: +1 609 524 0065
  • Email: mmp@genmab.com
  • Andrew Carlsen, Vice President, Head of Investor Relations
  • Phone: +45 3377 9558
  • Email: acn@genmab.com

Forward-Looking Statements and Disclaimer

This announcement includes forward-looking statements. Genmab cautions that actual results may differ materially due to various risks, including uncertainties related to clinical development and market acceptance. For more details, please refer to Genmab’s latest financial reports and the Annual Report on Form 20-F available through the U.S. Securities and Exchange Commission.

For additional information about Genmab and its products including DARZALEX®, please visit Genmab.com.

Related News